Q BioMed Inc. announced it has engaged EVERSANA?, the pioneer of next generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89, an FDA-approved cancer bone palliation radiotherapy. Strontium89 (Strontium Chloride Sr-89 Injection, USP) is the only approved radiotherapy currently available in the U.S. indicated for metastatic cancer bone pain palliation. In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for three months compared with a placebo. Further, new pain sites were less frequent in patients treated with Strontium89. Strontium89 is administered once every three months via injection, and patients can be re-treated if needed. To support and accelerate the product's rollout in the U.S., Q BioMed will leverage the EVERSANA COMPLETE Commercialization model which fully integrates services for: market access, agency services, clinical and commercial field teams, health economics and outcomes research and compliance. Each service is optimized by data and predictive analytics. The ready-to-deploy commercial platform is complemented by more than 5,500 EVERSANA employees and a dedicated commercialization leadership team, replacing Kristin Keller who is leaving Q BioMed. The EVERSANA field force and commercial team will augment an in-place contract sales force focused on the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD).